NO20061479L - Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser - Google Patents

Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser

Info

Publication number
NO20061479L
NO20061479L NO20061479A NO20061479A NO20061479L NO 20061479 L NO20061479 L NO 20061479L NO 20061479 A NO20061479 A NO 20061479A NO 20061479 A NO20061479 A NO 20061479A NO 20061479 L NO20061479 L NO 20061479L
Authority
NO
Norway
Prior art keywords
treatment
cyclosporins
hcv
disorders
modified
Prior art date
Application number
NO20061479A
Other languages
English (en)
Norwegian (no)
Inventor
Makoto Hijikata
Kunitada Shimotohno
Koichi Watashi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20061479L publication Critical patent/NO20061479L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20061479A 2003-09-03 2006-03-31 Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser NO20061479L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds
PCT/EP2004/009804 WO2005021028A1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders

Publications (1)

Publication Number Publication Date
NO20061479L true NO20061479L (no) 2006-06-02

Family

ID=28686843

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061479A NO20061479L (no) 2003-09-03 2006-03-31 Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser

Country Status (30)

Country Link
US (1) US7968518B2 (el)
EP (2) EP1663287B1 (el)
JP (1) JP4688806B2 (el)
KR (1) KR101116968B1 (el)
CN (1) CN1842343A (el)
AU (2) AU2004268382A1 (el)
BR (1) BRPI0414062B8 (el)
CA (1) CA2537137C (el)
CY (1) CY1110506T1 (el)
DE (1) DE602004022061D1 (el)
DK (1) DK1663287T3 (el)
ES (1) ES2328361T3 (el)
GB (1) GB0320638D0 (el)
HK (1) HK1091732A1 (el)
HR (1) HRP20090535T1 (el)
IL (1) IL173909A (el)
IS (1) IS2917B (el)
MA (1) MA28032A1 (el)
MX (1) MXPA06002394A (el)
NO (1) NO20061479L (el)
NZ (1) NZ545495A (el)
PL (1) PL1663287T3 (el)
PT (1) PT1663287E (el)
RU (1) RU2389501C2 (el)
SG (1) SG149063A1 (el)
SI (1) SI1663287T1 (el)
TN (1) TNSN06071A1 (el)
TW (1) TWI342782B (el)
WO (1) WO2005021028A1 (el)
ZA (1) ZA200601550B (el)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4350898B2 (ja) 1998-07-01 2009-10-21 デビオファーム・ソシエテ・アノニム 活性の特徴が改善された新規のシクロスポリン
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
US7671017B2 (en) 2004-07-14 2010-03-02 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
DK1802650T3 (da) * 2004-10-01 2012-02-06 Scynexis Inc 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
JP4892486B2 (ja) * 2004-10-01 2012-03-07 デビオファーム ソシエテ アノニム Ｃ型肝炎感染の治療のための［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンの使用、及び当該［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンを含む医薬組成物
US7696167B2 (en) 2004-11-22 2010-04-13 Astellas Pharma Inc. Cyclic peptide compound
CN101084005A (zh) * 2004-12-23 2007-12-05 诺瓦提斯公司 用于黄病毒科治疗的化合物
US7897565B2 (en) * 2004-12-23 2011-03-01 Novartis Ag Compositions for HCV treatment
WO2006138507A1 (en) * 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
NZ567262A (en) * 2005-09-30 2011-12-22 Scynexis Inc Cyclosporin derivatives and their use for the treatment and prevention of hepatitis C infection
CA2623864C (en) 2005-09-30 2014-12-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
RU2423377C2 (ru) 2005-10-26 2011-07-10 Астеллас Фарма Инк. Новые циклические пептидные соединения
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
JP5377293B2 (ja) 2006-05-19 2013-12-25 スシネキス インク 眼疾患の治療及び予防方法
WO2007141395A1 (fr) * 2006-06-02 2007-12-13 Claude Annie Perrichon Gestion des electrons actifs
JP5455632B2 (ja) * 2006-10-12 2014-03-26 ノバルティス アーゲー 修飾シクロスポリンの使用
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008084368A2 (en) * 2007-01-04 2008-07-17 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
EP2150269B1 (en) * 2007-05-02 2012-11-21 Astellas Pharma Inc. New cyclic peptide compounds
US20110158908A1 (en) 2007-08-24 2011-06-30 Sapporo Medical University Cyclosporin a-binding protein
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
EP2280989B1 (en) * 2008-06-06 2016-02-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
JP5726733B2 (ja) * 2008-07-30 2015-06-03 シクロフィリン ファーマシューティカルズ コープ． 非免疫抑制性シクロスポリン類似体分子
JP5625910B2 (ja) * 2008-09-24 2014-11-19 アステラス製薬株式会社 ペプチド化合物およびその製造方法
BRPI0920502A2 (pt) * 2008-11-06 2015-12-22 Debio Rech Pharma Sa compostos cicloundecadepsipeptídeos e seu uso como medicamento
AU2009334790B2 (en) * 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
AU2010208071C1 (en) 2009-01-30 2013-06-20 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
EP2509615A1 (en) 2009-12-09 2012-10-17 Scynexis, Inc. Novel cyclic peptides
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2012045704A1 (en) 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
CA2818067A1 (en) 2010-11-30 2012-06-07 Novartis Ag New treatments of hepatitis c virus infection
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
BR112013014890B1 (pt) 2010-12-15 2023-10-24 Contravir Pharmaceuticals, Inc Composto análogo de moléculas pertencentes à família ciclosporina, composição farmacêutica compreendendo o mesmo, uso terapêutico ou profilático do referido composto e processos para a preparação dos mesmos
KR20140007927A (ko) 2011-03-31 2014-01-20 노파르티스 아게 C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르
TW201247216A (en) 2011-04-01 2012-12-01 Novartis Ag Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis delta virus and associated liver diseases
CN103648516A (zh) 2011-04-13 2014-03-19 诺华股份有限公司 使用阿拉泊韦治疗丙型肝炎病毒感染
CN103826654A (zh) 2011-09-27 2014-05-28 诺华股份有限公司 用于治疗丙型肝炎病毒感染的阿拉泊韦
WO2013169616A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmacokinetic modulation with alisporivir
WO2013181339A2 (en) 2012-06-01 2013-12-05 Allergan, Inc. Cyclosporin a analogs
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
US9221878B2 (en) 2013-08-26 2015-12-29 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
EP0484281B2 (en) * 1990-11-02 2000-11-22 Novartis AG Cyclosporins
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
ATE211726T1 (de) 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
DE69830756T2 (de) 1997-04-04 2006-05-04 Mitsubishi Pharma Corp. 2-Aminopropan-1,3-diol-Verbindungen, ihre medizinische Anwendung und Zwischenprodukte zu ihrer Synthese
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
JP4350898B2 (ja) 1998-07-01 2009-10-21 デビオファーム・ソシエテ・アノニム 活性の特徴が改善された新規のシクロスポリン
CZ200350A3 (cs) 2000-07-13 2003-05-14 Sankyo Company Limited Aminoalkoholové deriváty
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
EP1372695A2 (en) * 2000-10-19 2004-01-02 Fujisawa Pharmaceutical Co., Ltd. Cell damage inhibitor
JP2002125683A (ja) * 2000-10-27 2002-05-08 Tokyoto Igaku Kenkyu Kiko インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ
CZ20032560A3 (cs) 2001-03-26 2003-12-17 Novartis Ag Deriváty 2-aminopropanolu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003029184A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
US20030213603A1 (en) * 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
US7662798B2 (en) 2002-06-28 2010-02-16 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
GB0313444D0 (en) 2003-06-11 2003-07-16 Midland Medical Technologies L Modular dysplasia cup
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP4892486B2 (ja) 2004-10-01 2012-03-07 デビオファーム ソシエテ アノニム Ｃ型肝炎感染の治療のための［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンの使用、及び当該［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンを含む医薬組成物
US7897565B2 (en) 2004-12-23 2011-03-01 Novartis Ag Compositions for HCV treatment

Also Published As

Publication number Publication date
GB0320638D0 (en) 2003-10-01
RU2389501C2 (ru) 2010-05-20
MXPA06002394A (es) 2006-06-20
BRPI0414062A (pt) 2006-10-24
AU2004268382A1 (en) 2005-03-10
PT1663287E (pt) 2009-09-03
EP1797892A1 (en) 2007-06-20
DK1663287T3 (da) 2009-11-09
IL173909A0 (en) 2006-07-05
ZA200601550B (en) 2007-05-30
KR20060132798A (ko) 2006-12-22
US7968518B2 (en) 2011-06-28
BRPI0414062B8 (pt) 2021-05-25
JP2007504260A (ja) 2007-03-01
IL173909A (en) 2011-03-31
EP1663287A1 (en) 2006-06-07
PL1663287T3 (pl) 2009-12-31
JP4688806B2 (ja) 2011-05-25
HK1091732A1 (en) 2007-01-26
EP1663287B1 (en) 2009-07-15
TWI342782B (en) 2011-06-01
EP1797892B1 (en) 2013-10-23
CA2537137A1 (en) 2005-03-10
TNSN06071A1 (en) 2007-10-03
SG149063A1 (en) 2009-01-29
CA2537137C (en) 2013-05-28
US20070275884A1 (en) 2007-11-29
NZ545495A (en) 2010-01-29
KR101116968B1 (ko) 2012-03-14
CY1110506T1 (el) 2015-04-29
IS2917B (is) 2014-12-15
SI1663287T1 (sl) 2009-10-31
ES2328361T3 (es) 2009-11-12
IS8371A (is) 2006-03-24
HRP20090535T1 (hr) 2009-11-30
WO2005021028A1 (en) 2005-03-10
RU2006110533A (ru) 2007-10-10
AU2008203031A1 (en) 2008-07-31
CN1842343A (zh) 2006-10-04
DE602004022061D1 (de) 2009-08-27
MA28032A1 (fr) 2006-07-03
BRPI0414062B1 (pt) 2019-06-25
TW200524626A (en) 2005-08-01
AU2008203031B2 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
NO20073765L (no) Forbindelser for behandling av flaviviridae
MA30893B1 (fr) Inhibiteurs de la protease ns3 du vhc
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
NO20073764L (no) Sammensetninger for behandling av HCV
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
EA200901241A1 (ru) Соединения для лечения гепатита с
NO20083694L (no) Bruk av rylener som markorer for vaesker
NO20081086L (no) Makrosykliske peptider som HCV NS3-proteaseinhibitorer
WO2006119061A3 (en) Hcv ns3 protease inhibitors
HK1108703A1 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
MXPA05008126A (es) Inhibidores de girasa y uso de los mismos.
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
WO2007109105A3 (en) Flavivirus inhibition by sultams and related compounds
EA201070423A1 (ru) Диарильные соединения оксадиазолов
EA201000329A1 (ru) Циклические депсипептиды
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
NO20076515L (no) Hydantoinforbindelser
DK1373220T3 (da) Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application